Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $7.08 Average Price Target from Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have received a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $7.0833.

Several brokerages have recently issued reports on XERS. Wall Street Zen cut shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Leerink Partners raised their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Tuesday, August 19th. HC Wainwright began coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th.

Insider Activity

In other news, Director Dawn Halkuff sold 42,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total value of $309,400.00. Following the transaction, the director owned 115,000 shares in the company, valued at approximately $837,200. This trade represents a 26.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Marla Persky sold 15,500 shares of the firm’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $7.72, for a total value of $119,660.00. Following the completion of the sale, the director directly owned 142,000 shares of the company’s stock, valued at $1,096,240. The trade was a 9.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 207,732 shares of company stock worth $1,550,437 over the last ninety days. Company insiders own 6.47% of the company’s stock.

Institutional Trading of Xeris Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Voya Investment Management LLC lifted its stake in Xeris Biopharma by 866.6% in the third quarter. Voya Investment Management LLC now owns 400,079 shares of the company’s stock worth $3,257,000 after acquiring an additional 358,689 shares during the period. Corient Private Wealth LLC purchased a new stake in Xeris Biopharma in the second quarter worth $320,000. Osaic Holdings Inc. lifted its position in Xeris Biopharma by 9.7% during the second quarter. Osaic Holdings Inc. now owns 42,709 shares of the company’s stock valued at $199,000 after buying an additional 3,774 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Xeris Biopharma by 7.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock valued at $150,000 after buying an additional 2,264 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Xeris Biopharma by 1,679.1% during the 2nd quarter. Squarepoint Ops LLC now owns 284,567 shares of the company’s stock valued at $1,329,000 after buying an additional 268,572 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS opened at $7.99 on Monday. Xeris Biopharma has a one year low of $2.78 and a one year high of $8.51. The firm’s 50 day simple moving average is $7.63 and its two-hundred day simple moving average is $5.74. The stock has a market capitalization of $1.29 billion, a P/E ratio of -38.05 and a beta of 0.39.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The business had revenue of $67.71 million for the quarter, compared to the consensus estimate of $64.58 million. As a group, equities analysts expect that Xeris Biopharma will post -0.41 earnings per share for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.